Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page annual report packed with optical genome mapping jargon can stall even seasoned analysts. Bionano Genomics annual report 10-K simplified is more than a paperwork chore鈥攊t's the key to understanding how instrument placements drive consumable pull-through and how R&D spending shapes future cash needs. If you've ever wished Bionano Genomics SEC filings explained simply, you're not alone.
Stock Titan鈥檚 AI decodes every disclosure in real time. Need the latest Bionano Genomics quarterly earnings report 10-Q filing or a concise Bionano Genomics 8-K material events explained summary? Our platform delivers both, plus side-by-side Bionano Genomics earnings report filing analysis that highlights segment revenue shifts and gross-margin trends. Interactive dashboards turn understanding Bionano Genomics SEC documents with AI into a two-minute task鈥攏o more line-item treasure hunts.
Curious whether insiders are buying Saphyr鈥檚 promise? Track Bionano Genomics insider trading Form 4 transactions with instant alerts. Our feed captures Bionano Genomics Form 4 insider transactions real-time, flags sizable Bionano Genomics executive stock transactions Form 4, and links them back to the proxy for context on Bionano Genomics proxy statement executive compensation. From patent milestones in 8-Ks to dilution risks disclosed in 10-Qs, Stock Titan surfaces what moves the stock鈥攕o you can act on data, not dense prose.
Bionano Genomics, Inc. reported interim unaudited results showing recurring losses and cash constraints. As of June 30, 2025 the company held $3.6 million in cash and cash equivalents, $12.9 million in short-term investments, $11.0 million in restricted short-term investments and working capital of $18.5 million. The company had $12.1 million principal outstanding under its senior secured convertible debentures and an accumulated deficit of $703.2 million. The company used $6.3 million of cash in operations during the six months ended June 30, 2025 and management stated there is substantial doubt about its ability to continue as a going concern without raising additional capital. Management expects operating losses and negative cash flows to continue for at least the next year and believes existing resources are sufficient into at least the first quarter of 2026 assuming current plans. Significant financing and conversion activity included a reverse stock split (1-for-60), registered direct offerings in January 2025 (~$10.0 million gross proceeds) and at-the-market sales under an ATM Agreement with H.C. Wainwright in 2025 (multiple tranches totaling millions in gross proceeds). Restructuring actions in 2023 and 2024 reduced headcount and caused related charges and impairments previously recorded.
Bionano Genomics (NASDAQ: BNGO) has filed an 8-K/A to amend its previous filing from June 13, 2025, correcting voting results for two key proposals. The amendment specifically addresses errors in reporting Broker Non-Votes and Votes For on Proposals 3 and 4.
Key Corrections:
- Proposal 3 (Ratification of BDO USA as auditor): Corrected to show 0 Broker Non-Votes instead of previously reported 769,744
- Proposal 4 (Warrant Exercise Share Issuance): Updated to show 396,176 Votes For (previously 369,176) and 769,744 Broker Non-Votes (previously unreported)
The corrections do not affect the outcome of either vote. Proposal 4 approved the issuance of up to 661,374 shares of common stock related to warrant exercises from a January 3, 2025 securities purchase agreement with institutional investors, in compliance with Nasdaq Listing Rule 5635(d).
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
